Global Prevalence of ATTR-CM in Participants With HFpEF
-
- STATUS
- Not Recruiting
-
- participants needed
- 347
-
- sponsor
- Pfizer
Updated on 17 June 2025
Summary
This study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population [participants with heart failure with preserved ejection fraction (HFpEF)].
Details
| Condition | Transthyretin Amyloid Cardiomyopathy, Heart Failure With Preserved Ejection Fraction |
|---|---|
| Age | 60years or above |
| Clinical Study Identifier | NCT04424914 |
| Sponsor | Pfizer |
| Last Modified on | 17 June 2025 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.